Abstract: The invention relates to the new N-[2-/4-fluorophenyl/-1-methyl]-ethyl-N-methyl-N-propynyl amine of the Formula I ##STR1## and isomers and salts thereof. The compound of the formula I is useful as a selective MAO inhibitor.

Abstract: The invention relates to a process for the preparation of tetracycline derivatives of the formula ##STR1## and acid addition salts thereof --wherein R stands for --CH.sub.3 or .dbd.CH.sub.2 --by dehalogenating and hydrogenating chloromethacycline or acid addition salt thereof of the formula ##STR2## or by hydrating methacycline or acid addition salts thereof of the formula ##STR3## by treatment with hydrogen gas in the presence of a noble metal alloy catalyst on carrier and organic solvent which comprises performing, hydrogenating under pressure of 0.1-1.0 MPa with an alloy catalyst consisting of the alloy palladium or platinum and selenium and/or tellurium used at a ratio of 1:0.01-0.5 related to the amount of the starting tetracycline and carrying out, if desired dehalogenation and hydrogenation in one step.

Abstract: The present invention relates to new compounds of Formula I ##STR1## and physiologically acceptable salts thereof wherein A and B stand for oxygen or --CH.sub.2 group with the proviso that if A stands for oxygen, then B stands for --CH.sub.2 group and R stands for hydrogen and, if A represents a --CH.sub.2 group, then B stands for oxygen, R stands for a --CH.sub.2 Q group wherein Q stands for hydrogen, and pyrrolidino, piperidino or morpholino and a process for the preparation thereof and pharmaceutical compositions containing as active ingredient a compound of the Formula (I) or a physiologically acceptable salt thereof.

Abstract: The present invention relates to synergistic arthropodicidal composition of several pyrethroidal active ingredients causing no damage to warm-blooded organisms comprising pyrethroides and piperonyl butoxide as active ingredient which comprises as pyrethroidal active ingredient 0.1-20% by weight of 1StransR-alpha-cyano-3-phenoxy-benzyl-3- (2,2-dichlorvinyl)-2,2-dimethyl/cyclopropane-cyrboxylate of the Formula I ##STR1## 0.05-10% by weight of cis-trans-tetramethrin (3,4,5,6-tetrahydrophthalimido-methyl(1RS)-cis-trans-chrysantemate) or trans-tetramethrin of the Formula II ##STR2## and a further pyrethroide, 0.

Abstract: The invention relates to pesticidal composition against bacterial plant diseases comprising as active ingredient a nitrofurane derivative of the general Formula I ##STR1## wherein X represents a group of the Formula a/ ##STR2## and optionally one or more known fungicidal active ingredient/s/ in a total amount of 1-99% by weight, whereby the ratio of the active ingredient of the general Formula I to the known fungicidal active ingredient/s/ amounts to 1:99-99:1, preferably 1:9-9:1 if the composition comprises two active ingredients and 1:9:0.5-1:1:5, preferably 1:4:1-1:1:4 if the composition comprises three active ingredients, respectively, in admixture with suitable inert solid or liquid carrier/s/ or diluent/s/ and usual auxiliary agents such as wetting agents, dispersing agents, adhesives, antifoaming agents and/or antifreezers.

Abstract: The invention relates to a plant-protective solution containing 2.5 to 40 % by weight of one or more water-insoluble plant-protective ingredient(s) 20 to 71.5 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 10 to 71.5 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 1 to 15 % by weight of commonly used additives such as anionic and/or nonionic surface active agents and macromolecules.The invention also relates to the ready-for-use plant-protective suspension containing 0.2 to 10 % by weight of one or more water-insoluble plant-protective ingredient(s) with a particle size of 0.1 to 50 .mu.m, 0 to 60 % by weight of a fertilizer, 0.2 to 10 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 0.2 to 10 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 0.05 to 2.

Abstract: The invention relates to new quinoline-3-carboxylic acid anhydride intermediates of the Formula I ##STR1## wherein R stands for cyclopropyl, a group of the Formula --CH.sub.2 CR.sup.5 R.sup.6 R.sup.7 wherein R.sup.5, R.sup.6 and R.sup.7 stand for hydrogen or halogen, or phenyl optionally substituted by 1 or 2 halogen,R.sup.1 and R.sup.2 stand for halogen, or an aliphatic acyloxy group containing 2 to 6 carbon atoms optionally substituted by halogen, or an aromatic acyloxy group containing 7 to 11 carbon atoms,R.sup.3 stands for chlorine or fluorine andR.sup.4 stands for hydrogen or fluorine. The compounds of the Formula I are new intermediates for the preparation of known quinoline-3-carbocxylic acids showing antibacterial activity.

Abstract: Diuretic and saluretic tetrahydro-isoquinoline derivatives of the Formula (I) ##STR1## wherein R stands for hydrogen or chlorine,R.sup.1 and R.sup.2 are hydrogen, methoxy or ethoxy, andR.sup.3 and R.sup.4 are hydrogen or methyl,and a process for the preparation thereof as well as pharmaceutical compositions containing as active ingredients isoquinoline derivatives of the Formula (I). The compounds of Formula I are prepared by reacting a 2-amino-tetrahydro-isoquinoline derivative of the Formula (II) ##STR2## with a carboxylic acid derivative of the Formula (III) ##STR3## wherein x stands for chlorine, --OH, --OCH.sub.2 CN, --OCH.sub.3, --OC.sub.2 H.sub.5, --OCOOCH.sub.3 or --OCOOC.sub.2 H.sub.5R.sup.5 and R.sup.6 stand for hydrogen or together from CHN(CH.sub.3).sub.2 and in case of the Formula (Ia) ##STR4## splitting off the protective group in alkaline medium.

Abstract: The invention relates to a new and simple process for the preparation of quinoline-carboxylic acid derivatives of the general formula (I) ##STR1## as well as hydrates and therapeutically acceptable salts thereof. In the formula the meaning of the substituents is as follows:R is hydrogen atom or a formyl group,R.sup.1 is a hydrogen atom or a straight or branched chain alkyl group having 1 to 4 carbon atoms, which may be substituted by a hydroxyl group, a halogen atom or an amino group; or a CH.sub.3 --NH-group,R.sup.2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.According to the invention the compound of the general formula (II) ##STR2## or an acid addition salt thereof is reacted with piperazine in dimethylformamide and--if desired--the compound of the general formula (III) ##STR3## thus obtained is subjected to an acidic or alkaline treatment, or is reacted advantageously with hydrazine or preferably with hydrazine-hydrate.

Abstract: The compounds of the Formula I ##STR1## (wherein R is hydrogen or halogen) and pharmaceutically acceptable acid addition salts thereof are suitable for the prophylaxis of undesired and unfavorable symptoms (e.g. perspiration, nausea, vomiting, dizziness, etc.) which occur when healthy humans or mammal animals are subjected to unusual moving (e.g. during transportation on aeroplane, or vehicles, ships, etc.

Abstract: The present invention relates to novel compounds of the general formula ##STR1## wherein R is hydrogen atom or a trifluoromethyl, carboxy, C.sub.2-5 alkoxycarbonyl, cyano, benzoyl, sulfamoyl or C.sub.1-4 alkylsulfonyl group;R.sup.1 is hydrogen atom or a linear or branched chain C.sub.1-4 alkyl, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfonyl, benzylthio, benzylsulfonyl, phenyl, hydroxy or mercapto group; andR.sup.2 is hydrogen or chlorine atom,as well as their pharmaceutically acceptable salts.The compounds according to the invention possess diuretic and saluretic activity with an advantageous Na/K ratio.

Abstract: The invention relates to a synergistic, antimicrobial pharmaceutical composition containing 0.01 to 50% by weight of a quinolinecarboxylic acid derivative or a naphthyridinecarboxylic acid derivative of the formula (I), ##STR1## wherein X is carbon or nitrogen;R.sup.1 is hydrogen or fluorine;R.sup.2 is methyl, piperazino or methylpiperazino group; orR.sup.1 and R.sup.2 together are a methylenedioxy group; and 0.01 to 95% by weight of a tetracycline derivative of the formula (II), ##STR2## wherein R.sup.3 and R.sup.4 are hydrogen; orR.sup.3 and R.sup.4 together represent an additional chemical bond,in 20:1 to 1:50 ratio of the compound of the formula (I) to the compound of the formula (II), optionally in an admixture with an amount required to 100% by weight of an inert, solid or liquid carrier such as magnesium carbonate, magnesium stearate, starch, talc, cyclodextrine or water and other additives such as filling, disintegrating, sliding and emulsifying agents.

Abstract: The invention relates to a synergistic pharmaceutical composition, which comprises as an active ingredient a combination of 1-phenylalanine and (-)-deprenyl [(-)-N-(1-phenylisopropyl)-N-methyl-N-propinylamine hydrochloride] and optionally carbidopa [3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methyl-propionic acid monohydrate] or benzerazide [N-(DL-seryl)-N'-( 2,3,4-trihydroxybenzyl)-hydrazine] in association with conventional inert, non-toxic solid or liquid pharamaceutical carriers. The invention further relates to the preparation of these compositions and to the use thereof for the treatment of depressive symptoms.

Abstract: The present invention relates to a process for the preparation of compounds of the general Formula I ##STR1## and pharmaceutically acceptable salts thereof (wherein R stands for piperazinyl or 4-methyl-piperazinyl) which comprises reacting a compound of the general Formula II ##STR2## (wherein R.sup.1 and R.sup.2 stand for halogen; an aliphatic acyloxy group comprising 2-6 carbon atoms and optionally substituted by halogen; or an aromatic acyloxy group comprising 7-11 carbon atoms) with a piperazine of the general Formula III ##STR3## (wherein R.sup.3 represent hydrogen or methyl) or a salt thereof, hydrolysing the compound of the general Formula IV ##STR4## thus obtained (wherein R, R.sup.1 and R.sup.2 are as stated above) without or after hydrolysis and if desired converting the compound of the general Formula I thus obtained into a salt thereof or setting free the same from its salt.The compounds of the general Formula I are known antibacterial agents.

Abstract: The invention relates to a process for the preparation of 3,4-dihydroisoquinoline by dehydrogenation of the 1,2,3,4-tetrahydroisoquinoline with elemental sulphur.

Abstract: The invention relates to novel racemic or optically active berban derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 represent independently from the other a hydroxyl, straight or branched chain alkoxy group 1 to 6 carbon atoms or R.sup.1 and R.sup.2 together represent a C.sub.1-3 alkylenedioxy group;R.sup.3 and R.sup.4 represent independently from the other hydrogen, straight or branched chain alkyl group, having 1 to 6 carbon atoms and optionally substituted by hydroxyl group, or a C.sub.2-6 alkoxycarbonyl or cyano group; andR.sup.5 represents hydrogen, straight or branched chain alkyl group having 1 to 6 carbon atoms, C.sub.1-7 aliphatic or aromatic acyl group or C.sub.1-7 alkylsulphonyl or arylsulphonyl group, anda salt thereof, to pharmaceutical compositions containing them, to the use as well as to process for preparing the novel compounds. The compounds of the formula (I) are selective .alpha..sub.

Abstract: According to the present invention there is provided a synergistic insecticidal composition containing more than one active ingredients and being harmless to environment characterized by comprising in an amount of from 0.001 to 99% by weight a synthetic pyrethroid of the Formula /I/ ##STR1## namely substantially only the 1RtransS and 1StransR entantiomer-pair /Ib/ out from the possible eight isomers--optionally in admixture with an amount of up to 100% by weight of one or more activator/s/ and auxiliary agent/s/, particularly antioxidants, stabilizing agents, wetting agents, emulsifying agents, dispersing agents, antifoam agents, dileunts and/or fillers.The enantiomer-pair Ib consisting of the 1RtransS and 1StransR isomers is new and the invention also relates to the said new enantiomer-pair and a process for the preparation thereof.

Abstract: The invention relates to new oxidiazole-alkyl-purine-derivatives of the Formula I ##STR1## and pharmaceutically acceptable salts thereof wherein A stands for C.sub.1-4 alkylene andR.sup.1 represents C.sub.1-6 alkyl, hydroxyalkyl, halogenoalkyl, carboxyalkyl, C.sub.5-6 cycloalkyl or aminoalkyl of the Formula --(CH.sub.2).sub.n --NR.sup.2 R.sup.3 in which group n is an integer 1-3; R.sup.2 and R.sup.3 each stand for hydrogen or C.sub.1-4 alkyl or together with the adjacent nitrogen atom they are attached to form a 5- or 6-membered nitrogen containing heterocyclic ring which may optionally comprise a further nitrogen atom or an oxygen atom as heteroatom; orR.sup.1 stands for phenyl, hydroxyphenyl, carboxyphenyl, benzyl or dimethoxybenzylThe compounds of the Formula I can be prepared by methods known per se and can be used in therapy as antitussive agents.

Abstract: The invention relates to a process for the preparation of high-purity gamma- and alpha-cyclodextrin starting from a starch substrate of low reducing capacity, partially hydrolysed with alpha-amylase. According to the invention a starch substrate of low reducing capacity partially hydrolysed with alpha-amylase is converted with cyclodextrin glucosyl transferase, after the addition of an aliphatic ketone of the formula R.sub.1 COR.sub.2, in which R.sub.1 and R.sub.2 stand for a straight or branched chained alkyl group having from 1 to 6 carbon atoms, and/or a phenol derivative of the formula R.sub.3 R.sub.4 PheOH, wherein R.sub.3 and R.sub.4 are hydrogen, alkyl having from 1 to 4 carbon atoms, or R.sub.3 and R.sub.4 together form phenyl group, Phe stand for phenyl group, OH is hydroxyl and/or a benzene derivative of the formula R.sub.5 R.sub.6 Phe, wherein R.sub.5 and R.sub.6 are hydrogen, alkyl having from 1 to 4 carbon atoms, or R.sub.5 and R.sub.

Abstract: The invention relates to a process for the preparation of a new crystalline monohydrate of 1-(3', 4'-diethoxy-benzyl-6, 7-diethoxy-3,4-dihydro-isoquinolinium-theophylline-7-acetate and if desired of pure 1-(3', 4'-diethoxy-benzyl)-6,7-diethoxy-3, 4-dihydro-isoquinolinium-theophylline-7-acetate free of contaminating oxidation products which comprises reacting 1-(3',4'-diethoxy-benzyl)-6,7-diethoxy-3,4-dihydro-isoquinolinium with theophylline-7-acetate acid in the presence of water and one or more organic solvent(s) and if desired dehydrating the 1-(3',4'-diethoxy-benzyl) 6,7-diethoxy-3,4-dihydro-isoquinolinium-theophyl line-7-acetate-monohydrate thus obtained.